fda warning letter semaglutide october 2025 letters glp-1 news Drug Recalls and Warnings: Recalls for Compounded and Tirzepatide, Wegovy; Facility FDA Warning Breakdown: Sterility – fda warning letters compounding semaglutide

The troubleshooting guide for weight loss stalls on semaglutide explores reasons beyond dosing errors that can affect outcomes, including diet, activity level, sleep, and metabolic factors

Not all pigmented lesions present at birth are CMNs

In a new study released by the scientific journal Addiction, there was a 40% lower rate of opioid overdose in those taking GLP-1s compared with those who didnt take the weight-loss drugs

Regulatory T cells exhibit distinct features in human breast cancer

Naltrexone-bupropion (Contrave) primarily causes nausea rather than diarrhea, affecting approximately 30% of users initially